Navigation Links
Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain
Date:9/11/2009

LISBON, Portugal, September 11 /PRNewswire/ --

- Head to Head Study Confirms Superiority of the New Intranasal Treatment for Breakthrough Cancer Pain Over OTFC

New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer. The study concludes that pain relief was significantly greater for Instanyl compared to OTFC at all time points:

    - 25% of episodes showed meaningful pain relief already at 5 minutes
      after treatment with Instanyl, as compared to 7% with OTFC.
      (p<0.001)[1]

    - 51% of the Instanyl treated patients had a meaningful pain relief at 10
      minutes, as compared to 24% with OTFC. (p<0.001)[1]

    (Logo:http://www.newscom.com/cgi-bin/prnh/20090909/358726 )

"These data confirm the superiority of the intranasal drug administration over OTFC. Rapid pain relief is essential for the management of breakthrough cancer pain and with evidence of onset of pain relief as early as 5 minutes, Instanyl offers patients a much more effective pain control than OTFC," said Professor Sebastiano Mercadante, principal investigator of the comparative study and Director of the Anesthesia and Intensive Care and Pain Relief and Palliative Care Units at La Maddalena Cancer Center, Palermo, Italy.

The study also showed that patients found Instanyl significantly easier to administer than OTFC, with 90% of patients finding Instanyl 'easy' or 'very easy' to use, compared to 40% of OTFC patients.[2] Instanyl is the First intranasal treatment for breakthrough cancer pain to be licensed and The study showed that 77% of patients preferred Instanyl to OTFC.[2]

"With a preference for Instanyl more than three-fold higher compared to OTFC, the study confirms that with Instanyl patients now have a treatment that they feel better matches their need," said Professor Mercadante and concluded: "Instanyl represents a major step forward in the management of breakthrough cancer pain."

Up to 95% of patients with cancer pain experience breakthrough pain,[3] Of which two-thirds experience inadequate pain control.[4] Interim results From the first European survey of breakthrough cancer pain[5] also presented for the first time in Lisbon show that on average a patient will have 3 episodes of BTCP per day, each one lasting on average 60 minutes and 96% of episodes being rated as moderate or severe. 87% of patients reported that their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people.

"Breakthrough cancer pain afflicts a large proportion of cancer patients, yet there is a significant under-treatment and sub-optimal treatment of these patients. Time has come for a change in management of breakthrough cancer pain and with Instanyl now approved we have an intranasal product with fast onset of pain relief, short duration which is easy to use. This will enable us to improve the care of cancer patients," commented President of EFIC, Professor Giustino Varrassi, Dept. of Anesthesiology and Pain Medicine L'Aquila University, Italy.

Instanyl is approved for the management of breakthrough cancer pain in adults already receiving maintenance opioid therapy for chronic cancer pain. This first-in class drug was granted marketing authorisation on the 20th July 2009, and will be launched across Europe from September 2009.

About Nycomed

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of EUR3.4 billion in 2008 and an adjusted EBITDA of EUR1.2 billion.

    For more information visithttp://www.nycomed.com

    About the study

    - A multinational, open-label, crossover trial comparing Instanyl(R) and
      Actiq(R) for breakthrough cancer pain in patients receiving chronic
      opioid treatment.

    - The trial investigated the efficacy of Instanyl compared to Actiq as
      well as ease of administration and patient preference.

    - Primary efficacy measurement was time to onset of meaningful pain
      relief.

    - Of 196 patients enrolled and 139 randomised, 86 patients completed the
      trial.

    Results showed that:

    - 25.3% of episodes showed meaningful pain relief (greater than or equal
      to 33% reduction in PI score) at 5 minutes after treatment with
      Instanyl versus 6.8% with Actiq.

    - 51% of the Instanyl treated patients had a meaningful pain relief
      (greater than or equal to 33% reduction in PI score) at 10 minutes
      versus 23.6% with Actiq.

    - 90% of patients found Instanyl was 'easy' or 'very easy' to use versus
      40% for Actiq.

    - 77% of patients preferred Instanyl to Actiq.

    - Both treatments were well tolerated with adverse events experienced
      being those typical for this group of opioid drugs.

References

1. Mercadante S, Radbruch L, Popper L, Korsholm L, Davies A; Efficacy of intranasal fentanyl spray (INFS) versus oral transmucosal fentanyl citrate (OTFC) for breakthrough cancer pain: an open-label crossover trial. Abstract presented at EFIC 2009.

2. Mercadante S, Radbruch L, Popper L, Korsholm L, Davies A; Ease of use and preference for intranasal fentanyl spray (INFS) versus oral transmucosal fentanyl citrate (OTFC) for breakthrough cancer pain. Abstract presented at EFIC 2009.

3. Zeppetella G. Ribeiro MD. Pharmacotherapy of cancer-related episodic pain. Expert Opin. Pharmacother. 2003;4:493-502

4. Davis MP, Walsh D, Lagman R, LeGrand SB. Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005;6:696-704.

5. Davies A, Zeppetella G, Sjoland K-F et al. European Survey of Breakthrough Cancer Pain. Poster presented at EFIC 2009.

For further information:

Media: Ulf Jonson, Senior International Brand Manager, Nycomed: +45-46-77-10-78


'/>"/>
SOURCE Nycomed
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
2. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
3. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
4. Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
5. Angiomax Will Retain Decision Resources Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
6. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
7. Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
8. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
9. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
10. Siemens Introduces New Standard of Care for Breast Ultrasound
11. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... HICKORY, N.C. , March 23, 2017  Transportation ... accolades as an end-to-end supply chain management firm with ... of Consumer Product Solutions Rick Zaffarano was ... Star of the Supply Chain by the only publication ... the global food supply chain. "Rick has ...
(Date:3/23/2017)... 2017 Summary ... pipeline guide Primary Hyperoxaluria - Pipeline Review, H1 ... (Genito Urinary System And Sex Hormones) pipeline landscape. ... by recurrent kidney and bladder stones. It results ... Symptoms include blood in the urine, pain when ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... report to their offering. ... The global oxygen therapy devices market to grow ... The report, Global Oxygen Therapy Devices Market 2017-2021, has been ... experts. The report covers the market landscape and its growth prospects ...
Breaking Medicine Technology:
(Date:3/24/2017)... Oakland, CA (PRWEB) , ... March 24, 2017 ... ... present on two panels at the Advanced ERISA Benefit Claims Litigation seminar in ... and Creating the Administrative Record, The majority of cases litigated under ERISA involve ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, The Dog Who Barks ... lives his life to the fullest, as God intended. “The Adventures of Joey, The ... mother and grandmother pursuing her passion for writing, especially about truth and human behavior. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Dilger-Maxwell ... of the Norwalk and Vermillion areas, celebrates the newest charity campaign in ... nonprofit, community-based substance abuse prevention and peer recovery support organization providing vital ...
Breaking Medicine News(10 mins):